STOCK TITAN

Arcus Biosciences, Inc. - $RCUS STOCK NEWS

Welcome to our dedicated page for Arcus Biosciences news (Ticker: $RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcus Biosciences's position in the market.

Rhea-AI Summary
Arcus Biosciences, Inc. (RCUS) granted new employees options to purchase 12,600 shares of common stock and 6,300 restricted stock units under its 2020 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
Rhea-AI Summary
Arcus Biosciences (RCUS) to Participate in Fireside Chat at Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
conferences
-
Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) announced the grant of equity awards to new employees, including options to purchase 31,200 shares of common stock and restricted stock units for 15,600 shares. The awards were granted under the 2020 Inducement Plan approved by the Board of Directors in January 2020.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.15%
Tags
none
Rhea-AI Summary
Arcus Biosciences, Inc. (NYSE:RCUS) reports financial results for Q3 2023 and provides pipeline update. Domvanalimab shows promising results in Phase 2 EDGE-Gastric study for upper GI cancers. AB521 exhibits consistent results in cancer patients. Arcus expects to fund operations into 2026 with $950 million in cash and equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
-
Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce promising results from the Phase 2 EDGE-Gastric study, showing encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate in patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. Six-month PFS rates were 93% and 68% for PD-L1-high and PD-L1-low tumors, respectively. Detailed results will be presented at the ASCO Monthly Plenary Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce positive results from the Phase 2 EDGE-Gastric study, showing promising overall response rate (ORR) and six-month progression-free survival (PFS) rate. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. The six-month PFS rate was 93% for PD-L1-high tumors and 68% for PD-L1-low tumors. The regimen was well tolerated with a similar safety profile to anti-PD-1 plus chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
Rhea-AI Summary
Arcus Biosciences grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
Rhea-AI Summary
Arcus Biosciences to present data from Phase 2 study of domvanalimab at ASCO Monthly Plenary Series
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
conferences earnings
-
Rhea-AI Summary
Arcus Biosciences grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
Rhea-AI Summary
Arcus Biosciences grants equity awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

RCUS Stock Data

1.54B
54.39M
41.17%
59.82%
9.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
HAYWARD

About RCUS

arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be